140
Participants
Start Date
June 23, 2025
Primary Completion Date
June 22, 2027
Study Completion Date
June 22, 2027
Popliteal nerve block including liposomal bupivacaine
10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
Adductor canal nerve block including liposomal bupivacaine
10 mL of unencapsulated bupivacaine 0.375% and 10 mL of liposomal bupivacaine 1.33% (Exparel, Pacira BioSciences, Tampa, Florida) admixed within a 20 mL syringe.
Continuous popliteal nerve block with normal saline
A perineurial infusion of normal saline (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
Popliteal nerve block with exclusively unencapsulated bupivacaine
20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
Adductor canal nerve block with exclusively unencapsulated bupivacaine
20 mL of unencapsulated bupivacaine 0.375% with epinephrine (1:400,000) within a 20 mL syringe.
Continuous popliteal nerve block with unencapsulated bupivacaine
A perineurial infusion of unencapsulated bupivacaine 0.125% (basal rate 5 mL/h; patient-controlled bolus of 4 mL; 30 minute lockout) with the reservoir (500 mL) and pump provided by the Investigational Drug Service and continued until postoperative day 3 or until the reservoir is exhausted.
University of California San Diego, La Jolla
Collaborators (1)
Pacira Biosciences
UNKNOWN
University of California, San Diego
OTHER